Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
High Resolution Image Download MS PowerPoint Slide Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as anticancer drugs, but their clinical utility has been limited. To address these limitations, we have developed a novel class of “bi-steric inhibitors” that interact with both the orthosteric and the allosteric binding sites in order to deepen the inhibition of mTORC1 while also preserving selectivity for mTORC1 over mTORC2. In this report, we describe the discovery and preclinical profile of the development candidate RMC-5552 and the in vivo preclinical tool compound RMC-6272. We also present evidence that selective inhibition of mTORC1 in combination with covalent inhibition of KRAS G12C shows increased antitumor activity in a preclinical model of KRAS G12C mutant NSCLC that exhibits resistance to KRAS G12C inhibitor monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Figure 5 (A) Local resolution map of the mTORC1-RMC-5552-FKBP12 cryo-EM structure (PDB 8ERA). Higher resolution core of the map allows for confident modeling of side chains and both the rapalog-like and the ATP-competitive moieties of RMC-5552. N-HEAT domain of mTOR (right) and WD40 domain of Raptor (left) are more disordered than other regions of the map and consequently approach 7 Å. (B) Cryo-EM map of mTORC1-FKBP12-RMC-5552 38 complex. mTORC1-FKBP12-RMC-5552 38 complex cryo-EM map is shown colored by protomer. Blue is mTOR, green is Raptor, purple is mLST8, and red is FKBP12. (C) Cryo-EM map reveals density for rapalog moiety of RMC-5552 38 binding at its expected location between FKBP12 and the FRB domain at threshold 0.0033. (D) Cryo-EM map reveals density corresponding to the ATP-competitive moiety of RMC-5552 38 (orange) binding mTOR (blue) at its orthosteric site at threshold 0.024. Multiple hydrogen bonds are formed between mTOR and ligand, including with mTOR residues K2187, E2190, G2238, and V2240 (black dashed lines). 4-Aminopyrazolo[3,4-d]pyrimidine core of RMC-5552 π stacks with the aromatic side chain of mTOR residue W2239 (purple dashed line). Density (gray transparent surface) does not extend beyond the beginning of the linker region.](https://figures.cochat.ai/paper-figures/fa7711cac0f845929c9c0e9597ecfc74/discovery-of-rmc-5552-a-selective-bi-steric-inhibitor-of-mtorc1-for-the-figure-5.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · cited 1×
“45 Inhibition of mTOR has been of historical interest to the pharmaceutical industry, with rapamycin 1 being approved as an immunosuppressant in 1999.”
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase
Harding, M. W., Galat, A., Uehling, D. E., & Schreiber, S. L. (1989) · Nature · doi:10.1038/341758a0 · Cited by 1,396
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
KINO, T., HATANAKA, H., HASHIMOTO, M., NISHIYAMA, M., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., & IMANAKA, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1249 · Cited by 1,241
KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., et al. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1256 · Cited by 1,209
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075 · cited 2×
“In addition, bi-steric inhibitor 31 , which contains an active-site inhibitor based on XL388 (entry 3), also displayed potent on-target mTORC1 inhibition (p4EBP1 IC 50 = 0.70 nM) with a moderate degree of mTORC1/mTORC2 selectivity (ratio = 4.1).”
InfluentialSiekierka, J. J., Hung, S. H. Y., Poe, M., Lin, C. S., & Sigal, N. H. (1989) · Nature · doi:10.1038/341755a0 · Cited by 1,010
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 834
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 696
Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K.-I., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 682
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40
Yang, H., Jiang, X., Li, B., Yang, H. J., Miller, M., Yang, A., Dhar, A., & Pavletich, N. P. (2017) · Nature · doi:10.1038/nature25023 · Cited by 548 · cited 1×
“87,88 For instance, Scaiola et al. showed that the C-terminal (CT) domain of Rictor sits on top of the mTOR FRB domain in mTORC2, blocking the binding of FKBP-rapamycin to mTORC2 and explaining mTORC2 insensitivity to rapamycin.”
Yang, Q., & Guan, K.-L. (2007) · Cell Research · doi:10.1038/cr.2007.64 · Cited by 535
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494 · cited 4×
“Other bi-steric compounds, such as 30 , were also susceptible to a similar ring-opening process to yield significant amounts of a seco-species after dosing to rats (data not shown).”
InfluentialOvercoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Inhibition of the immune response by rapamycin, a new antifungal antibiotic
Martel, R. R., Klicius, J., & Galet, S. (1977) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y77-007 · Cited by 463
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates
Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S., & Kozarich, J. W. (2007) · Biochemistry · doi:10.1021/bi062142x · Cited by 418
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Immunopurified Mammalian Target of Rapamycin Phosphorylates and Activates p70 S6 Kinase α in Vitro
Isotani, S., Hara, K., Tokunaga, C., Inoue, H., Avruch, J., & Yonezawa, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34493 · Cited by 336
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Blair, H. A. (2021) · Drugs · doi:10.1007/s40265-021-01574-2 · Cited by 241
Research progress of mTOR inhibitors
Chen, Y., & Zhou, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112820 · Cited by 197 · cited 1×
“47 Rapamycin and its analogs (termed rapalogs) are first-generation mTOR inhibitors and inhibit mTORC1-mediated phosphorylation of S6K but only weakly inhibit phosphorylation of 4EBP1 and have negligible effects on mTORC2.”
Musa, J., Orth, M. F., Dallmayer, M., Baldauf, M., Pardo, C., Rotblat, B., Kirchner, T., Leprivier, G., & Grünewald, T. G. P. (2016) · Oncogene · doi:10.1038/onc.2015.515 · Cited by 170
Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.
BAKER, H., SIDOROWICZ, A., SEHGAL, S. N., & VÉZINA, C. (1978) · The Journal of Antibiotics · doi:10.7164/antibiotics.31.539 · Cited by 166
Human brain tumor xenografts in nude mice as a chemotherapy model
Houchens, D. P., Ovejera, A. A., Riblet, S. M., & Slagel, D. E. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90012-3 · Cited by 163
Chemical modification of rapamycin: the discovery of SDZ RAD
Sedrani, R. C., Cottens, S., Kallen, J. A., & Schüler, W. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00587-9 · Cited by 155
Atomic structure of the rapamycin human immunophilin FKBP-12 complex
Van Duyne, G. D., Standaert, R. F., Schreiber, S. L., & Clardy, J. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00019a057 · Cited by 148
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., & Milella, M. (2018) · Cancers · doi:10.3390/cancers10010023 · Cited by 141
Brown, W. S., McDonald, P. C., Nemirovsky, O., Awrey, S., Chafe, S. C., Schaeffer, D. F., Li, J., Renouf, D. J., Stanger, B. Z., & Dedhar, S. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100131 · Cited by 111
Rapamycin: FK506's fraternal twin or distant cousin?
Morris, R. E. (1991) · Immunology Today · doi:10.1016/s0167-5699(05)80040-4 · Cited by 107
The 3.2-Å resolution structure of human mTORC2
Scaiola, A., Mangia, F., Imseng, S., Boehringer, D., Berneiser, K., Shimobayashi, M., Stuttfeld, E., Hall, M. N., Ban, N., & Maier, T. (2020) · Science Advances · doi:10.1126/sciadv.abc1251 · Cited by 105
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Zhang, Y., Yan, H., Xu, Z., Yang, B., Luo, P., & He, Q. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1663169 · Cited by 99
Venditti, J. M., WESLEY, R. A., & Plowman, J. (1984) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60263-x · Cited by 94
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J. W., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00813-7 · Cited by 82
Self-citationPaine, M. F., Leung, L. Y., Lim, H., Liao, K., Oganesian, A., Zhang, M.-Y., Thummel, K. E., & Watkins, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.174 · Cited by 49 · cited 1×
“Comparable seco-species are a well-known degradant from rapamycin itself (where it is known as secorapamycin 34 ), which forms in vivo, 91,92 under enzymatic processes (CYP 3A4) 89,90 and under basic conditions.”
Wang, C. P., Chan, K. W., Schiksnis, R. A., Scatina, J., & Sisenwine, S. F. (1994) · Journal of Liquid Chromatography · doi:10.1080/10826079408013519 · Cited by 42
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang, S. S., & Nagasaka, M. (2021) · Lung Cancer: Targets and Therapy · doi:10.2147/lctt.s334623 · Cited by 41
Studies on the chemistry of rapamycin: Novel transformations under Lewis-acid catalysis
Luengo, J. I., Konialian, A. L., & Holt, D. A. (1993) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)77473-9 · Cited by 38 · cited 1×
“72,74,75 Testing of the seco-products 32 and 33 , formed from bi-steric inhibitors 16 and 30 , respectively, indicated that they were much less potent as mTORC1 or mTORC2 inhibitors (Table 4).”
Degradation of rapamycin and its ring-opened isomer: Role of base catalysis
Il’ichev, Y. V., Alquier, L., & Maryanoff, C. A. (2007) · ARKIVOC · doi:10.3998/ark.5550190.0008.c09 · Cited by 34
The isolation, synthesis and characterization of an isomeric form of rapamycin
Hughes, P. F., Musser, J., Conklin, M., & Russo, R. (1992) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)61273-x · Cited by 30
New Insights into Drug Absorption
Paine, M. F., Leung, L. Y., & Watkins, P. B. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200410000-00001 · Cited by 30 · cited 1×
“Comparable seco-species are a well-known degradant from rapamycin itself (where it is known as secorapamycin 34 ), which forms in vivo, 91,92 under enzymatic processes (CYP 3A4) 89,90 and under basic conditions.”
Base catalyzed degradations of rapamycin
Steffan, R. J., Kearney, R. M., Hu, D. C. K., Failli, A. A., Skotnicki, J. S., Schiksnis, R. A., Mattes, J. F., Chan, K. W. S., & Caufield, C. E. (1993) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)79204-5 · Cited by 29
Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity
Jessen, K. A., Wang, S., Kessler, L. V., Guo, X., Kucharski, J. M., Staunton, J., Lan, L., Elia, M., Stewart, J., Brown, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b148 · Cited by 25
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
Lee, B. J., Mallya, S., Dinglasan, N., Fung, A., Nguyen, T., Herzog, L.-O., Thao, J., Lorenzana, E. G., Wildes, D. P., Singh, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673213 · Cited by 19
Self-citationWang, C. P., Lim, H., Chan, K. W. S., Scatina, J., & Sisenwine, S. F. (1995) · Journal of Liquid Chromatography · doi:10.1080/10826079508009308 · Cited by 17
Studies on selective reductions of rapamycin
Luengo, J. I., Rozamus, L. W., & Holt, D. A. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)78248-7 · Cited by 11
Derivation of Rapamycin: Adventures in Natural Product Chemistry
Cottens, S., Kallen, J., Schüler, W., & Sedrani, R. C. (2019) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2019.581 · Cited by 10 · cited 2×
“72,73 72 − 75 To complicate matters further, rapamycin and close analogs exist as two interconvert-ing hemiketal structural isomers.”
Burris, H. A., Ulahannan, S. V., Haura, E. B., Ou, S. I., Capasso, A., Münster, P. N., Kitai, H., Wang, Z., Hayes, J. L., Lin, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.3098 · Cited by 7
Self-citationWang, C. P., Lim, H., Chan, K. W. S., Scatina, J., & Sisenwine, S. F. (1997) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826079708006326 · Cited by 5
Abstract B108: 4EBP3 mRNA as a biomarker of therapeutic response to treatment with mTORC1 inhibitors
Lee, B. J., Dinglasan, N., Nguyen, T., Lorenzana, E., Wilson, S. L., Burnett, G. L., Aggen, J. B., Nichols, R. J., Singh, M., Wildes, D. P., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-b108 · Cited by 2
Self-citationRostovtsev, V. V., Green, L. G., Fokin, V. V., & Sharpless, K. B. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4
Research works printed but not linked: 23
- Sehgal S. N.; Blazekovic T. M.; Vezina C. Rapamycin und seine herstellung. Patent application number DE 1973-2347682, 1973; Chem Abstr.1974, 81, 24166.
- Sehgal S. N.; Blazekovic T. M.; Vézina C. Rapamycin and process of preparation. U.S. Patent 3,929,992, 1975; Chem Abstr.1976, 85, 3861.
- Sehgal S. N.; Blazekovic T. M.; Vezina C. Rapamycin and process of preparation. U.S. Patent 3,993,749, 1976; Chem Abstr.1977, 86, 41806.
- Sidorowicz H.; Baker H.; Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic: in vitro and in vivo studies. 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 24–26, 1975, Washington, DC; American Society for Microbiology, 1975; Abstract 26.
- Morris R. E.; Meiser B. M. Identification of a new pharmacologic action for an old compound. Med. Sci. Res. 1989, 17, 609– 610.
- a Sehgal S. N.; Vézina C. Compositions pharmaceutiques à base de rapamycine pour le traitement de tumeurs carcinogens. Patent number BE 877700, 1980; Chem Abstr.1980, 93, 88940. See also. b Sehgal S. N.; Vézina C. US Patent Application Number 957626, 1978.
- Eng C. P. Combination of rapamycin and picibanil for the treatment of tumors. U.S. Patent 4,401,653, 1983; Chem Abstr.1983, 98, 22284.
- Shokat K.; Okaniwa M. mTORCl inhibitors. WO 2016040806, 2016; Chem Abstr.2016, 164, 412316.
- Ren P.; Liu Y.; Li L.; Chan K.; Wilson T. E. Benzoxazole kinase inhibitors and methods of use. WO 2010051043, 2010; Chem Abstr.2010, 152, 542024.
- Semko C.; Pitzen J.; Wang G.; Tibrewal N.; Aggen J. B.; Thottumkara A. P.; Burnett G. L.; Gliedt M. J. E.; Kiss G.; Won W.; Lee J. C.; Gill A. L. Rapamycin analogs as mTOR inhibitors. WO 2018204416, 2018; Chem Abstr.2018, 169, 525729.
- Pitzen J.; Gliedt M. J. E.; Burnett G. L.; Aggen J. B.; Kiss G.; Cregg J. J.; Semko C. M.; Won W.; Wang G.; Lee J. C-L.; Thottumkara A. P.; Gill A. L.; Mellem K. T. C40-, C28-, and C32-linked rapamycin analogs as mTOR inhibitors. WO 2019212990, 2019; Chem Abstr.2019, 171, 558403.
- Semko C. M.; Wang G.; Burnett G. L.; Aggen J. B.; Kiss G.; Cregg J. J.; Gliedt M. J. E.; Pitzen J.; Lee J. C-L.; Won W.; Thottumkara A. P.; Gill A. L. C26-linked rapamycin analogs as mTOR inhibitors. WO 2019212991, 2019; Chem Abstr.2019, 171, 551179.
- Mahauad-Fernandez W. D.; Yang Y. C.; Lai I.; Park J.; Yao L.; Evans J. W.; Burnett L. G.; Gill A.; Smith J. A. M.; Singh M.; Felsher D. W. Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy; https://www.biorxiv.org/content/10.1101/2022.02.04.478208v1. · doi:10.1101/2022.02.04.478208v1
- Tibrewal N.; Aggen J. B.; Bassan A. I.; Burnett G. L.; Evans J.; Gliedt M. J.; Hsieh T.; Kiss G.; Lee B. J.; Lee D.; Lorenzana E.; Marquez A.; Thottumkara A.; Wang Z.; Wilson S.; Zhao F.; Goldsmith M. A.; Singh M.; Wildes D.; Gill A. L.; Smith J. A. M. 4EBP1 reactivation by potent and selective bi-steric inhibitors of mTORC1. Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling, 2018 Nov 30–Dec 8; Boston, MA; American Association for Cancer Research: Philadelphia, PA, 2018; Poster PR04.
- Yang Y. C.; Jiang J.; Schulze C.; Evans J. W.; Reyes D. F.; Choy T.; Nguyen T.; Wang Z.; Lee D.; Nichols R. J.; Wang Z.; Smith J. A. M.; Kelsey S. M.; Singh M. Positioning a selective, bi-steric inhibitor of mTORC1 as a combination partner in RAS-driven cancers. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020, Virtual Meeting II, June 22–24, 2020; American Association for Cancer Research: Philadelphia, PA, 2020; Poster LB-113.
- Burnett G. L.; Pitzen J.; Gliedt M.; Semko C. M.; Jiang J.; Yang Y. C.; Schulze C. J.; Marquez A.; Evans J. W.; Wilson S. L.; Hsieh T.; Wang Z. C.; Lee B. J.; Choy T.; Reyes D. F.; Zhao Y.; Tao J. Y.; Du H.; Ozawa T.; Fan Q.; Luo K.; Kiss G.; Wildes D. P.; Raleigh D.; Wang Z. P.; Monga S. P.; Kwiatkowski D. J.; Weiss W. A.; Aggen J.; Singh M.; Smith J. A. M.; Gill A. Discovery of RMC-5552, a selective bi-steric inhibitor of mTORC1 that suppresses 4EBP1 phosphorylation, for the treatment of mTORC1-activated tumors including RAS pathway escape. Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I, Apr 10–15, 2021; American Association for Cancer Research: Philadelphia, PA, 2021; Presentation ND10.
- Mahauad-Fernandez W.; Yang Y. C.; Lai I.; Park J.; Evans J. W.; Singh M.; Smith J. A. M.; Felsher D. A bi-steric mTORC1 inhibitor that selectively reactivates 4EBP1 and induces regression of MYC-driven hepatocellular carcinoma. Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I, Apr 10–15, 2021; American Association for Cancer Research: Philadelphia, PA, 2021; Poster 1002.
- Du H.; Yang Y. C.; Singh M.; Liu H.; Kwiatkowski D. J. Bi-steric mTORC1-selective inhibitors demonstrate improved potency and efficacy in tumors with mTORC1 hyperactivation. Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I, Apr 10–15, 2021; American Association for Cancer Research: Philadelphia, PA, 2021; Poster 1026.
- Cottens S.; Sedrani R. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants. WO 9409010, 1994; Chem Abstr.1994, 122, 9774.
- Hu D. C. Preparation of rapamycin carbonate esters as immunosuppressant agents. U.S. Patent 5,260,300, 1993; Chem Abstr.1993, 120, 269937.
- Nelson F. C. 27-hydroxyrapamycin and derivatives thereof. U.S. Patent 5,256790, 1993; Chem Abstr.1993, 121, 9034.
- Cottens S.; Sedrani R. Synthesis and immunosuppressant activity of rapamycin derivatives. WO 9641807, 1996; Chem Abstr.1996, 126, 157342.
- Zhu T. Oxepane isomer of 42-O-(2-hydroxyethyl)rapamycin. U.S. Patent 7,241,771, 2007; Chem Abstr.2006, 145, 292763.
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
“Interestingly, bi-steric mTORi RMC-5552 [329] in combination with Ras inhibitors has exhibited clinical anticancer activity with a favourable safety profile in relapsed or refractory RAS-mutated solid tumor patients [330].”
BackgroundPI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
Hao, C., Wei, Y., Meng, W., Zhang, J., & Yang, X. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102861 · Cited by 100
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
Huth, S. W., Oakley, J. V., Seath, C. P., Geri, J. B., Trowbridge, A., Parker, D. L., Rodriguez‐Rivera, F. P., Schwaid, A. G., Ramil, C. P., Ryu, K. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03325 · Cited by 78
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
Wiese, W., Barczuk, J., Racińska, O., Siwecka, N., Rozpędek‐Kamińska, W., Słupianek, A., Sierpiński, R., & Majsterek, I. (2023) · Cancers · doi:10.3390/cancers15215297 · Cited by 87
“It is worth adding that the first clinical candidate in the class of bi-steric mTORC1 inhibitor (RMC-5552) is undergoing clinical trials in solid tumors (NCT04774952) [97].”
BackgroundTeng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Metadata
- Authors
- Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., Tomlinson, A. C. A., Kiss, G., Tzitzilonis, C., Thottumkara, A. P., Cregg, J., Mellem, K. T., Choi, J. S., Lee, J. C., Zhao, Y., Lee, B. J., Meyerowitz, J. G., Knox, J. E., Jiang, J., Wang, Z., Wildes, D., Wang, Z., Singh, M., Smith, J. A. M., & Gill, A. L.
- Affiliations
- Revolution Medicines (United States) (US)
- Corresponding author
- Burnett, G. Leslie
- Gill, Adrian L.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-12-19
- Volume
- 66
- Issue
- 1
- Pages
- 149-169
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC9841523
- OpenAlex
- W4311927080
- Cited by
- 72
- References
- 74
- Citations by year
- 2026: 25 · 2025: 19 · 2024: 11 · 2023: 17
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- mTORC1 inhibition, PI3K/mTOR pathway, KRAS G12C, non-small cell lung cancer, anticancer drug discovery
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.